摘要
Purpose: Ischaemic stroke remains a major cause of death and disability worldwide. Existing therapies do not target neuroprotection or regeneration. Neural stem cells (NSCs) have unique neuroregenerative, anti-inflammatory and neuroprotective properties. However, NSCs have limited migratory ability and experience low survivability within ischaemic environments. This study aimed to identify stroke induced chemokine signals, then genetically overexpress corresponding chemokine receptors in iPSC-NSCs to enhance their therapeutic efficacy.
Methodology: Photothrombotic (PT) stroke was induced in postnatal day (PND) 10 rat pups. Infarcted brain tissue was collected 24-hours later for chemokine analysis. Immunocytochemistry and qPCR were used to validate iPSC to NSC differentiation. Overexpression of CCR5 in iPSC-NSCs via lentiviral transduction was validated with flow cytometry and Boyden chamber. Therapeutic efficacy of genetically modified NSCs was compared with naïve NSCs in our PT model. Cells were administered at 24-hours post-stroke via an intra-arterial cannula into the carotid artery. A dose escalation study (1x106, 2.5x106 and 5x106 cells in 100µL PBS) was conducted. Animals were sacrificed 24-hours post-administration for migration and histological analyses, 3-days and 40-days for behavioural analyses.
Results: iPSC-NSCs maintained stemness up to passage 10. Chemokine analysis revealed upregulation of CCL3, the target ligand for CCR5. Lentiviral overexpression of CCR5 in NSCs was successful with 80% transduction efficiency. Preliminary Boyden chamber assays demonstrated increased migratory ability of CCR5-NSCs compared to naïve NSCs. Intra-arterial cell delivery was successfully optimised, with cell doses up to 5x106 well-tolerated without mortality. Preliminary data demonstrates successful migration of CCR5-NSCs to the ischaemic area. Ongoing work will investigate effect of dose-escalation and impact on infarct volume, microglial response and neuronal loss.
Conclusion: iPSC-NSCs with genetically enhanced migratory capacity has the potential to be a regenerative and neuroprotective adjunct therapy for ischaemic stroke. Intra-arterial delivery aligns well with current clinical treatment workflows, improving the translatability of this therapy.
